Merck & Co. has paused shipments of its cancer-preventing Gardasil vaccine to China until at least mid-year, further exacerbating concerns among investors and analysts. The move comes as the company faces a second major setback in the country this year, following a decline in vaccine demand in 2024 that sent shares tumbling.
The pause adds to perceptions of management credibility issues, with some analysts warning that it may impact the future of the blockbuster product. Despite repeated assurances from Merck that it had taken steps to address the issue, the company’s efforts have yet to stem the flow of declining sales in China.
Source: https://www.bloomberg.com/news/articles/2025-02-04/merck-halts-gardasil-sales-in-china-dragging-on-2025-outlook